CFDE Data Portal | Search MIR194-2HG

	Label	Description
	MIR194-2HG Gene (Entity type)	ENSG00000229719 - MIR194-2 host gene
	GSE195663 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE189035 inositol 2 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE238116 EGR1 HCC overexpression MHCC97-H PLC-PRF-5 3 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158552 BRD4 inhibition 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE224004 GSE224005 CHD4 EWS-FLI1 knockdown 0 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 5 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 paclitaxel 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE77261 SHARPIN knockdown MCF-7 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

MIR194-2HG

ENSG00000229719 - MIR194-2 host gene

GSE195663 cisplatin 0 v 1 human up

A Gene Set from LINCS

GSE189035 inositol 2 v 4 human dn

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human up

A Gene Set from LINCS

GSE238116 EGR1 HCC overexpression MHCC97-H PLC-PRF-5 3 v 0 human up

A Gene Set from LINCS

GSE158552 BRD4 inhibition 2 v 0 human dn

A Gene Set from LINCS

GSE224004 GSE224005 CHD4 EWS-FLI1 knockdown 0 v 8 human up

A Gene Set from LINCS

GSE113655 phenol 5 v 4 human dn

A Gene Set from LINCS

GSE172016 paclitaxel 2 v 1 human dn

A Gene Set from LINCS

GSE77261 SHARPIN knockdown MCF-7 0 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.